Men treated with ADT more likely to experience impaired cognitive performance
the ONA take:
Men treated with androgen deprivation therapy (ADT) for prostate cancer were more likely to demonstrate impaired cognitive performance within 6 months and for up to 12 months after initiation of ADT, a new study published online early in the Journal of Clinical Oncology has shown.
For the study, researchers at Moffitt Cancer Center in Tampa, Florida, sought to determine the effect of ADT on cognitive performance identify predictors of impaired performance. Researchers enrolled 58 patients with prostate cancer whom they assessed before or within 21 days of starting ADT and 6 and 12 months afterwards.
Participants were compared with matched controls with prostate cancer treated with prostatectomy as well as men with without prostate cancer.
Results showed that participants that received ADT had higher rates of impaired cognitive performance over time compared with all controls.
Researchers found that those who received ADT were more likely to exhibit impaired performance within 6 and 12 months versus the other two groups despite no differences in baseline characteristics.
Exploratory genetic analyses showed that GNB3 single-nucleotide polymorphism rs1047776 was associated with higher rates of impaired cognitive performance over time in patients treated with ADT.
The findings may result in changes to patient education regarding the benefits and risks of ADT.
Men treated with ADT for prostate cancer more likely to demonstrate impaired cognitive performance.
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- Directly Informing Patients of Breast Cancer Risk, Options Improves Follow-Up Screening
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Free Lung Cancer Screening Findings Support Continual Screenings in High-Risk Populations
- Parental Self-persuasion in Low-Income Groups Improves HPV Vaccination Rates
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Shared Decision-making Visits Improved Comfort With Lung Cancer Screening Decisions
- Temozolomide With Radiotherapy for Glioblastoma Provides Some Survival Benefit in Elderly
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|